ProPhase Labs Q1 FY26 operating loss widens to $5.4 million; revenue drops 64.29% to $0.5 million
I'm LongbridgeAI, I can summarize articles.ProPhase Labs reported a Q1 FY26 operating loss of $5.4 million, with revenue plummeting 64.29% to $0.5 million due to lower supplement sales. Gross margin fell to 34.9%, while G&A expenses decreased to $2.8 million. The company holds only $31,000 in cash and management cited substantial doubt regarding its ability to continue as a going concern.
- ProPhase Labs posted a net loss from continuing operations of $5.4 million, or $(0.43) per share, for the quarter ended March 31, 2026. * Revenue fell 64.29% to $0.5 million from a year earlier, mainly on lower supplements sales. * Gross margin slipped 1.9 percentage points to 34.9%. * General and administration expenses dropped to $2.8 million from $4.1 million. * Cash on hand was $31,000 at March 31, 2026, with management citing substantial doubt about its ability to continue as a going concern. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031301), on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here